97- Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in patients with
Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol.
2012;107:1409–22. - Mahadevan U, Kane S, Sandborn WJ, et al. Intentional inflimab use during pregnancy for induc-
tion or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther. 2005;21:733–8. - Jurgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn’s disease during pregnancy:
case report and review of the literature. Inflamm Bowel Dis. 2010;16:1634–6. - Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890.
- Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira)
for Crohn’s disease in pregnancy. Inflamm Bowel Dis. 2006;12:827–8. - Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s
disease of an ileoanal pouch during pregnancy. Dig Dis Sci. 2006;51:2045–7. - Johnson DL, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to adali-
mumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009;136:A27. - Burmester GR, Landewe R, Genovese MC, et al. Adalimumab long-term safety: infections,
vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann
Rheum Dis. 2017;76:414–7. - Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut. 2009;58:608.
- Clowse MEB, Wolf DC, Forger F, et al. Pregnancy outcomes in subjects exposed to certoli-
zumab pegol. J Rheumatol. 2015;42:2270–8. - Lau A, Clark M, Harrison DD, et al. Pregnancy outcomes in women exposed to the tumor
necrosis factor inhibitor, golimumab. Ann Rheum Dis. 2014;73:232–3. - Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflam-
matory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis.
2011;17:1846–54. - Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with
inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center
study. Scand J Gastroenterol. 2013;48:951–8. - Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-a
drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol.
2013;108:433–40. - Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF
treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–73. - Deepak P, Stobaugh D. Maternal and foetal adverse events with tumour necrosis factor-alpha
inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:1035–43. - Mahadevan U, Martin C, Sandler R, et al. PIANO: a 1000 patient prospective registry of
pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy.
Gastroenterology. 2012;142:S149. - Verstappen SMM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of
130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis.
2011;70:823–6. - Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome
following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observa-
tional study. Reprod Toxicol. 2014;43:78–84. - Komoto S, Motyoya S, Nishiwaki Y, et al. Pregnancy outcome in women with inflammatory
bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter
study from Japan. Intest Res. 2016;14:139–45. - Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-a
inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin
Pharmacol. 2015;80:727–39. - Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the World
Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and
Colitis Organization: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214–23. - Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College of
Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and
6 Biologics in Pregnancy and Breastfeeding